PharmChem, Inc. common stock is traded on the OTC/Pink Sheets under the symbol 'PCHM.PK'. On March 26, 2004, the Company filed Form 15 under Rule 12g-2 of the 1934 Securities Exchange Act, whereby all reports required to be filed by Section 13(a) - including Forms 10-K, 10-Q & 8-K - are immediately suspended. As a result, the Company does not submit financial and other reports to the Securities and Exchange Commission.

Our CUISP number is 717133

Our Transfer Agent is Transfer Online at http://transferonline.com

Phone: (503) 227 2950 Fax: (503) 227 6874

Disclosure Page on OTC Markets: https://www.otcmarkets.com/stock/PCHM/disclosure

PharmChem, Inc. Company Contacts:

Matt Katz - Chief Executive Officer mkatz@pharmchem.com

Kerri Wagner - Chief Revenue Officer kwagner@pharmchem.com

Shana Veale - VP & CFO sveale@pharmchem.com

Tice Brown - Chairman of the Board tice@pchmshareholders.com

Thompson Clark - Director

Tim Eriksen - Director

Harris Perlman - Director

Phone: 855-458-4100

Email: info@pharmchem.com

2411 E. Loop 820 N. Fort Worth, TX 76118

10/24/22 Q3 Financial Statements + Letter to Shareholders and OTCIQ Disclosure 8/31/2022 Shareholder Meeting Q&A 7/27/22 PharmChem Q2 Letter to Shareholders 4/22/22 Q1 Financial Statements + Letter to Shareholders and OTCIQ Disclosure 12/31/21 Letter to Shareholders + Unaudited Q4 Financials 9/30/21 Letter to Shareholders 6/30/21 Letter to Shareholders 12/31/20 Letter to Shareholders 6/30/20 Letter to Shareholders 2019 Letter to Shareholders 2018 Letter to Shareholders 2017 Letter to Shareholders 2016 Letter to Shareholders 2015 Letter to Shareholders 2014 Letter to Shareholders 2013 Letter to Shareholders 2012 Letter to Shareholders 2010 Letter to Shareholders 2004 Special Meeting of Shareholders